$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000115903620000044 Filed on November 02, 2020

Income Statement

Concept	2020 Q3	2019 Q3	2019 Q2
Revenue	$65.32M	$46.23M	$39.15M
YoY Change	41.28%	80.9%	11.21%
Cost Of Revenue	$5.568M	$22.33M	$1.877M
YoY Change	-75.07%	3467.57%	124.52%
Gross Profit	$3.480M	$6.872M	$3.883M
YoY Change	-49.36%	21.78%	6.47%
Gross Profit Margin	5.33%	14.86%	9.92%
Selling, General & Admin	$11.70M	$17.98M	$17.34M
YoY Change	-34.91%	20.96%	20.8%
% of Gross Profit	336.26%	261.63%	446.51%
Research & Development	$7.747M	$30.46M	$33.91M
YoY Change	-74.56%	-14.31%	-15.41%
% of Gross Profit	222.61%	443.18%	873.29%
Depreciation & Amortization	$800.0K	$1.000M	$1.000M
YoY Change	-20.0%	66.67%	66.67%
% of Gross Profit	22.99%	14.55%	25.75%
Operating Expenses	$25.02M	$70.77M	$53.13M
YoY Change	-64.65%	38.68%	-3.89%
Operating Profit	$40.30M	-$24.54M	-$13.98M
YoY Change	-264.24%	-3.68%	-30.37%
Interest Expense	$4.990M	$2.078M	$2.613M
YoY Change	140.13%	-51.52%	-45.22%
% of Operating Profit	12.38%
Other Income/Expense, Net	$961.0K	$1.613M	$1.983M
YoY Change	-40.42%	-15.55%	0.0%
Pretax Income	$36.27M	-$25.00M	-$14.61M
YoY Change	-245.07%	-10.23%	-36.1%
Income Tax	$63.00K	$13.00K	$17.00K
% Of Pretax Income	0.17%
Net Earnings	$36.21M	-$25.02M	-$14.62M
YoY Change	-244.74%	-10.18%	-36.12%
Net Earnings / Revenue	55.43%	-54.11%	-37.36%
Basic Earnings Per Share	$0.27	-$0.17	-$0.10
Diluted Earnings Per Share	$0.25	-$0.17	-$0.10
COMMON SHARES
Basic Shares Outstanding	136.6M shares	146.1M shares	145.4M shares
Diluted Shares Outstanding	142.1M shares	146.1M shares	145.4M shares

Balance Sheet

Concept	2020 Q3	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$346.7M	$238.0M	$287.5M
YoY Change	45.67%	-34.69%	-27.93%
Cash & Equivalents	$65.74M	$59.20M	$67.04M
Short-Term Investments	$281.0M	$178.8M	$220.4M
Other Short-Term Assets	$31.90M	$27.20M	$28.10M
YoY Change	17.28%	38.78%	32.55%
Inventory	$57.70M	$36.05M	$43.90M
Prepaid Expenses	$37.61M	$21.52M	$19.92M
Receivables	$62.55M	$40.74M	$32.22M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$498.9M	$342.0M	$391.7M
YoY Change	45.86%	-20.44%	-15.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.25M	$15.40M	$15.08M
YoY Change	-33.42%	126.77%	214.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$14.90M	$12.90M	$11.00M
YoY Change	15.5%	65.38%	39.24%
Total Long-Term Assets	$25.13M	$28.32M	$26.12M
YoY Change	-11.23%	94.19%	105.35%
TOTAL ASSETS
Total Short-Term Assets	$498.9M	$342.0M	$391.7M
Total Long-Term Assets	$25.13M	$28.32M	$26.12M
Total Assets	$524.0M	$370.4M	$417.8M
YoY Change	41.49%	-16.68%	-11.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$433.0K	$4.314M	$12.47M
YoY Change	-89.96%	29.51%	101.5%
Accrued Expenses	$25.80M	$45.68M	$45.56M
YoY Change	-43.53%	6.18%	30.06%
Deferred Revenue	$748.0K	$3.511M	$6.511M
YoY Change	-78.7%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$54.54M	$70.88M
YoY Change	-100.0%	-38.39%	-18.5%
Total Short-Term Liabilities	$26.98M	$108.0M	$135.4M
YoY Change	-75.03%	-22.34%	2.26%
LONG-TERM LIABILITIES
Long-Term Debt	$393.6M	$9.300M	$14.10M
YoY Change	4132.26%	-83.94%	-82.17%
Other Long-Term Liabilities	$3.793M	$6.407M	$6.532M
YoY Change	-40.8%	190.83%	182.28%
Total Long-Term Liabilities	$3.793M	$6.407M	$6.532M
YoY Change	-40.8%	190.83%	182.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.98M	$108.0M	$135.4M
Total Long-Term Liabilities	$3.793M	$6.407M	$6.532M
Total Liabilities	$30.77M	$114.4M	$141.9M
YoY Change	-73.12%	-19.02%	5.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$547.8M	-$569.3M	-$544.3M
YoY Change	-3.78%	7.55%	8.54%
Common Stock	$646.3M	$814.2M	$803.9M
YoY Change	-20.62%	5.81%	6.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$98.99M	$245.4M	$260.1M
YoY Change
Total Liabilities & Shareholders Equity	$524.0M	$370.4M	$417.8M
YoY Change	41.49%	-16.68%	-11.99%

Cashflow Statement

Concept	2020 Q3	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	$36.21M	-$25.02M	-$14.62M
YoY Change	-244.74%	-10.18%	-36.12%
Depreciation, Depletion And Amortization	$800.0K	$1.000M	$1.000M
YoY Change	-20.0%	66.67%	66.67%
Cash From Operating Activities	$6.100M	-$29.60M	-$24.80M
YoY Change	-120.61%	55.79%	31.91%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$1.100M	-$1.400M
YoY Change	-81.82%	266.67%	180.0%
Acquisitions
YoY Change
Other Investing Activities	-$29.90M	$42.10M	$48.90M
YoY Change	-171.02%	18.26%	-779.17%
Cash From Investing Activities	-$30.10M	$41.00M	$47.50M
YoY Change	-173.41%	16.48%	-725.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-43.90M	-19.20M	-16.30M
YoY Change	128.65%	17.07%	0.0%
NET CHANGE
Cash From Operating Activities	6.100M	-29.60M	-24.80M
Cash From Investing Activities	-30.10M	41.00M	47.50M
Cash From Financing Activities	-43.90M	-19.20M	-16.30M
Net Change In Cash	-67.90M	-7.800M	6.400M
YoY Change	770.51%	3800.0%	-114.99%
FREE CASH FLOW
Cash From Operating Activities	$6.100M	-$29.60M	-$24.80M
Capital Expenditures	-$200.0K	-$1.100M	-$1.400M
Free Cash Flow	$6.300M	-$28.50M	-$23.40M
YoY Change	-122.11%	52.41%	27.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	halo	Accountsreceivablefromroyalties Accountsreceivablefromroyalties	17149000	USD
CY2020Q3	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	4052000	USD
CY2019Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	3591000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136712480	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135369359	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136712480	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135369359	shares
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	797000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62551000	USD
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0179
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0256
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0031
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0135
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0135
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0022
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0022
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32335
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0488686
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11388 Sorrento Valley Road
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	794-8889
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	HALO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135183040	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65741000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120179000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	280965000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	301083000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62551000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59442000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	57697000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	29359000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31941000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33373000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	498895000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	543436000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10252000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10855000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	14382000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	11083000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2020Q3	us-gaap	Assets Assets	524029000	USD
CY2019Q4	us-gaap	Assets Assets	565874000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	433000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6434000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25795000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	55649000	USD
CY2020Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	748000	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4012000	USD
CY2020Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	19542000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	26976000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85637000	USD
CY2020Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	641000	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1247000	USD
CY2020Q3	us-gaap	Long Term Debt LongTermDebt	393631000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	383045000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3793000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4180000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	135000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	137000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	646184000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	695066000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	426000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	240000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-547757000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-603678000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	98988000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	91765000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	524029000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	565874000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65316000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46230000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145891000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142327000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5568000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22333000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17095000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28859000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7747000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30455000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26856000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95693000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11702000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17979000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35309000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53323000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	25017000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	70767000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	79260000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	177875000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	40299000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24537000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	66631000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35548000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	961000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1613000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4764000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5653000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4990000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	2078000	USD
	us-gaap	Interest Expense InterestExpense	15342000	USD
CY2020Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	32000000	USD
	us-gaap	Interest Expense InterestExpense	7896000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36270000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25002000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	56053000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37791000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	132000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	36207000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-25015000	USD
	us-gaap	Net Income Loss NetIncomeLoss	55921000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37843000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136578000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146136000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136575000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145435000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142081000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146136000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	139971000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145435000	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	36207000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-25015000	USD
	us-gaap	Net Income Loss NetIncomeLoss	55921000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37843000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-640000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	203000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	667000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	13000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	8000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-7000	USD
CY2019Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-9000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	35547000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25013000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	56107000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37174000	USD
	us-gaap	Net Income Loss NetIncomeLoss	55921000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37843000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13008000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	27547000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2484000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3026000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10540000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	763000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-477000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2205000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	631000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3870000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4497000	USD
	halo	Deferred Rent Payments DeferredRentPayments	759000	USD
	halo	Deferred Rent Payments DeferredRentPayments	304000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	525000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-13000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3109000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10739000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28338000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13426000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1567000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14310000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-40134000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6809000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4534000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58798000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	161488000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	241582000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	181345000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	362250000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	805000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3399000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	861000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19913000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	117269000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	19560000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	63298000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	109970000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	50645000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6093000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-78885000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-57205000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-54438000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1266000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120679000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58436000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66241000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59702000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	531000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	251000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1661000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	897000	USD
	halo	Pending Settlementof Common Stock Repurchase PendingSettlementofCommonStockRepurchase	2502000	USD
	halo	Pending Settlementof Common Stock Repurchase PendingSettlementofCommonStockRepurchase	0	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	105577000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4220000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12546000	USD
CY2020Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	58902000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-660000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	36207000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	98988000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	91765000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13008000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50645000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	112472000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	-65000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	186000	USD
	us-gaap	Net Income Loss NetIncomeLoss	55921000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	98988000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	260052000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8239000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2075000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59442000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	2000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-25015000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245353000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	248887000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27547000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6093000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	669000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37843000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245353000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"><span style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> drug delivery</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:10pt;">technology with the collaborators’ proprietary compounds.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> recombinant, (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> drug delivery technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (now members of the Takeda group of companies, following the acquisition of Shire plc by Takeda Pharmaceutical Company Limited in January 2019) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (“Alexion”) and ARGENX BVBA (“argenx”). We receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from royalties and fees from ENHANZE collaborations and the sales and/or royalties of our approved products will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div>The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2020Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	63793000	USD
	halo	Revenue Remaining Performance Obligation Period Of Termination By Written Notice RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice	P90D
CY2020Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15000000.0	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	36207000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-25015000	USD
	us-gaap	Net Income Loss NetIncomeLoss	55921000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37843000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136578000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146136000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136575000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145435000	shares
CY2020Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5503000	shares
CY2019Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3396000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142081000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146136000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	139971000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145435000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	280507000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	463000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	280965000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	300829000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	273000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	301083000	USD
CY2020Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	3	security
CY2020Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	27400000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	277880000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	274805000	USD
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	60239000	USD
CY2020Q3	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	1242000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3085000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	26278000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	280965000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	301083000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	346509000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	421032000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65316000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46230000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145891000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142327000	USD
	halo	Proceeds From Partner Of License And Collaborative Agreement ProceedsFromPartnerOfLicenseAndCollaborativeAgreement	114100000	USD
CY2020Q3	halo	Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets	30551000	USD
CY2019Q4	halo	Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets	59442000	USD
CY2020Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	32000000	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2020Q3	us-gaap	Deferred Revenue DeferredRevenue	1389000	USD
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	5259000	USD
CY2020Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1400000	USD
CY2020Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1400000	USD
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	700000	USD
CY2020Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	32000000.0	USD
CY2020Q3	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	933634000	USD
CY2020Q3	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	3198000	USD
CY2019Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	35649000	USD
CY2020Q3	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	476000	USD
CY2019Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	3850000	USD
CY2020Q3	halo	Accountsreceivablefromroyalties Accountsreceivablefromroyalties	24067000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5473000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2769000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	20953000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15710000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	31271000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10880000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	57697000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	29359000	USD
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	37606000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30156000	USD
CY2020Q3	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	550000	USD
CY2019Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	4964000	USD
CY2020Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3223000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3655000	USD
CY2020Q3	us-gaap	Other Assets OtherAssets	4944000	USD
CY2019Q4	us-gaap	Other Assets OtherAssets	5681000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	46323000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	44456000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	14382000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	11083000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31941000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33373000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	18363000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross Excluding Capital Leased Assets PropertyPlantAndEquipmentGrossExcludingCapitalLeasedAssets	17748000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	11786000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	10742000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	6577000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net Excluding Capital Leased Assets PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets	7006000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3675000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3849000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10252000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10855000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000.0	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	400000	USD
CY2019Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3000000.0	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1300000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1300000	USD
CY2020Q3	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	918000	USD
CY2019Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	8423000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7372000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27888000	USD
CY2020Q3	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	6946000	USD
CY2019Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	9173000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8765000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7876000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5523000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6469000	USD
CY2020Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	29524000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	59829000	USD
CY2020Q3	halo	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	3729000	USD
CY2019Q4	halo	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	4180000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25795000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	55649000	USD
CY2020Q3	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	100000	USD
CY2019Q3	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	200000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	USD
	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	400000	USD
	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	600000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2000000.0	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2500000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2300000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1389000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5259000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	748000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4012000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	641000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1247000	USD
CY2019Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	447400000	USD
CY2019Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	200000000.0	USD
CY2019Q4	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	6900000	USD
CY2019Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	2600000	shares
CY2019Q4	us-gaap	Repayments Of Debt RepaymentsOfDebt	26100000	USD
CY2019Q4	halo	Non Convertible Borrowing Ratefor Similar Debt Percent NonConvertibleBorrowingRateforSimilarDebtPercent	0.0519
CY2019Q4	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	65600000	USD
CY2019Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	447400000	USD
CY2020Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	591000000.0	USD
CY2019Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	461100000	USD
CY2020Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	2930000	USD
CY2019Q4	us-gaap	Repayments Of Debt RepaymentsOfDebt	26100000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4220000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8239000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13008000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27547000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4220000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8239000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13008000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27547000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	34700	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	100000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1500000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3000000.0	shares
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M24D
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	550000000.0	USD
CY2019Q4	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	6900000	USD
CY2020Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3188795	shares
CY2020Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	16.15
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	51574000	USD
CY2020Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	88307	shares
CY2020Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	22.58
CY2020Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1996000	USD
CY2020Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2134716	shares
CY2020Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	27.57
CY2020Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	58902000	USD
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5411818	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	20.76
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	112472000	USD
CY2020Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	500000	shares
CY2020Q1	halo	Treasury Stock Acquired Fee Cost Per Share TreasuryStockAcquiredFeeCostPerShare	0.02
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	771000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2594000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2535000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	130000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6030000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	507000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	5523000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D

Files In Submission

Name	View Source	Status
0001159036-20-000044-index-headers.html	Edgar Link	pending
0001159036-20-000044-index.html	Edgar Link	pending
0001159036-20-000044.txt	Edgar Link	pending
0001159036-20-000044-xbrl.zip	Edgar Link	pending
ex31110qq32020.htm	Edgar Link	pending
ex31210qq32020.htm	Edgar Link	pending
ex3210qq32020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
halo-20200930.xsd	Edgar Link	pending
halo-20200930_cal.xml	Edgar Link	unprocessable
halo-20200930_def.xml	Edgar Link	unprocessable
halo-20200930_lab.xml	Edgar Link	unprocessable
halo-20200930_pre.xml	Edgar Link	unprocessable
haloq320-10q.htm	Edgar Link	pending
haloq320-10q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slide1b46.jpg	Edgar Link	pending
slide2b29.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2020 Q3 Form 10-Q Financial Statement

#000115903620000044 Filed on November 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2020 Q3 Form 10-Q Financial Statement

#000115903620000044 Filed on November 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo